Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$2.48 CAD
Change Today -0.02 / -0.80%
Volume 1.6M
PLI On Other Exchanges
Symbol
Exchange
OTC US
Toronto
Frankfurt
As of 4:00 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

prometic life sciences inc (PLI) Snapshot

Open
C$2.52
Previous Close
C$2.50
Day High
C$2.55
Day Low
C$2.45
52 Week High
03/19/15 - C$2.87
52 Week Low
07/4/14 - C$1.00
Market Cap
1.4B
Average Volume 10 Days
2.3M
EPS TTM
C$-0.03
Shares Outstanding
573.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROMETIC LIFE SCIENCES INC (PLI)

Related News

No related news articles were found.

prometic life sciences inc (PLI) Related Businessweek News

No Related Businessweek News Found

prometic life sciences inc (PLI) Details

ProMetic Life Sciences Inc., a biopharmaceutical company, develops bio separations, plasma-derived therapeutics, and small-molecule drugs. The company offers its technologies for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, autoimmune disease/inflammation, and cancer. It operates in two segments, Therapeutics and Protein Technology. The Therapeutics segment’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. This segment is also developing PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases; and PBI-1402 for the treatment of anemia indications. The Protein Technology segment provides plasma protein purification system, a solution for the extraction and purification of therapeutic proteins from human plasma; bioseparation products based on applications of its patented Mimetic Ligand technology for various biopharmaceutical companies; and prion capture/pathogen removal technology platform that improves the safety profile of blood products and blood-derived therapeutics. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.

197 Employees
Last Reported Date: 03/31/15
Founded in 1992

prometic life sciences inc (PLI) Top Compensated Officers

Chief Executive Officer, President and Non-In...
Total Annual Compensation: C$489.1K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: C$404.7K
Chief Executive Officer of ProMetic BioScienc...
Total Annual Compensation: C$238.5K
Chief Medical Officer, Independent Director a...
Total Annual Compensation: C$267.6K
General Counsel and Corporate Secretary
Total Annual Compensation: C$229.2K
Compensation as of Fiscal Year 2014.

prometic life sciences inc (PLI) Key Developments

ProMetic Life Sciences Signs Emergent Plant in Winnipeg to Process Plasma

ProMetic Life Sciences Inc. announced that it has a new 15-year agreement for a Winnipeg manufacturing plant to process medical plasma using the company's proprietary purification method. The work will be done at a Emergent BioSolutions facility with the capacity to process up to 250,000 litres of plasma annually.

ProMetic Life Sciences Inc. Confirms Both Its Plasma-Derived and Small Molecule Therapeutics Platforms Enabling the Corporation to Expand Its Development Pipeline

ProMetic Life Sciences Inc. confirmed that it has successfully advanced both its plasma-derived and small molecule therapeutics platforms, enabling the Corporation to expand its development pipeline. The interim report on clinical results from its PBI-4050 open label phase II clinical trial in patients suffering from metabolic syndrome and resulting Type 2 diabetes; The interim report on clinical results from its PBI-4050 open label phase II clinical trial in patients suffering from idiopathic pulmonary fibrosis ("IPF"); The initiation of a PBI-4050 Phase II clinical trial in patients suffering from chronic kidney diseases associated with diabetes in the USA and in Canada; The initiation of PBI-4050 Phase II clinical trial in a subgroup of patients suffering from metabolic syndrome and fibrosis in Europe; The completion of the patient enrolment in the plasminogen clinical program and the pursuit of a new clinical indication; The completion of adult patients enrolment in the IVIG clinical program; The scale-up and preparation of the Alpha-1 Antitrypsin clinical program, for a phase I-III study; The scale-up and preparation of the C1-esterase inhibitor clinical program, for a phase I-III study; and The continued development of new bioprocesses to enable the production of further plasma-derived drug candidates.

ProMetic Life Sciences Inc. Announces Earnings Results for the First Quarter Ended March 31, 2015

ProMetic Life Sciences Inc. announced earnings results for the first quarter ended March 31, 2015. The company generated a net loss of CAD 20.4 million for the quarter ended March 31, 2015 compared to a net loss of CAD 8.7 million for the quarter ended March 31, 2014. Of the CAD 20.4 million net loss incurred in the first quarter of 2015, approximately CAD 9.5 million comes from the variation in fair value of the warrant liability and the loss on debt extinguishment which do not affect cash. Total revenues for the first quarter ended March 31, 2015 were CAD 1.9 million compared to CAD 5.7 million for the first quarter ended March 31, 2014. Revenues from the sale of goods amounted to CAD 1.4 million compared to CAD 3.2 million for the same period in 2014. Service revenues were CAD 0.5 million for the quarter ended March 31, 2015 compared to CAD 2.5 million for the quarter ended March 31, 2014. The decrease is due to lower product sales and the fact that services billed to NantPro are being eliminated upon consolidation due to its acquisition from a control perspective in May 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PLI:CN C$2.48 CAD -0.02

PLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PLI.
View Industry Companies
 

Industry Analysis

PLI

Industry Average

Valuation PLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 74.9x
Price/Book 24.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 74.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROMETIC LIFE SCIENCES INC, please visit www.prometic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.